BMC Complementary and Alternative Medicine, 18 (1), 26
Ongoing access without insurance requirements or membership fees makes continuous therapy affordable and practical for patients who want to avoid the regain cycle entirely
The most significant change for expensive brand-name drugs is the hard annual out-of-pocket cap of $2,000 [3]
DISCONTINUATION of glucagon-like peptide-1 (GLP-1) receptor agonist treatment could reverse cardiovascular benefits, increasing the risk of heart disease in adults with Type 2 diabetes, a 2026 target trial emulation has found
Furthermore, these mechanisms may underlie the use of the diabetes drug GLP-1 RA to treat AD and PD
Looking at a separate study of people with both obesity and type 2 diabetes, weight loss was understandably slightly lower diabetes medications and metabolic differences often blunt the response but still substantial